Pierachille Santus Selected Research

Muscarinic Antagonists

1/2022	A reappraisal of inspiratory capacity in chronic obstructive pulmonary disease: clinical correlates and role of long-acting muscarinic antagonists and long-acting β2 agonists.
11/2021	Switching to nebulised short acting bronchodilators does not increase the risk of arrhythmia in patients hospitalized with a COPD exacerbation.
1/2019	The Airways' Mechanical Stress in Lung Disease: Implications for COPD Pathophysiology and Treatment Evaluation.
1/2019	A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management.
12/2017	Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine.
11/2017	Acute effects of long-acting bronchodilators on small airways detected in COPD patients by single-breath N2 test and lung P-V curve.
1/2017	Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease.
1/2017	Symptom variability and control in COPD: Advantages of dual bronchodilation therapy.
1/2016	Effects of aclidinium on determinants of COPD severity: symptoms and quality of life.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pierachille Santus Research Topics

Disease

42	Chronic Obstructive Pulmonary Disease (COPD) 01/2024 - 01/2004
27	Asthma (Bronchial Asthma) 03/2023 - 01/2002
18	COVID-19 12/2023 - 01/2020
12	Inflammation (Inflammations) 01/2023 - 01/2002
7	Dyspnea (Shortness of Breath) 01/2023 - 12/2009
7	Respiratory Insufficiency (Respiratory Failure) 07/2022 - 01/2020
7	Pneumonia (Pneumonitis) 01/2022 - 10/2012
6	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2023 - 07/2012
4	Lung Diseases (Lung Disease) 01/2023 - 07/2012
2	Pathologic Constriction (Stenosis) 12/2023 - 01/2023
2	Bronchiectasis 01/2023 - 08/2022
2	Psoriasis (Pustulosis Palmaris et Plantaris) 10/2020 - 01/2018
2	Arthritis (Polyarthritis) 10/2020 - 01/2016
2	Hypoxia (Hypoxemia) 04/2020 - 08/2007
2	Cough 01/2017 - 12/2014
1	Tracheal Stenosis 12/2023
1	Respiratory Syncytial Virus Infections 11/2023
1	Heart Failure 11/2023
1	Fibrosis (Cirrhosis) 01/2023
1	Necrosis 01/2023
1	Ischemia 01/2023
1	Cystic Fibrosis (Mucoviscidosis) 08/2022
1	Frailty 07/2022
1	Post-Acute COVID-19 Syndrome 01/2022
1	Human Influenza (Influenza) 12/2021
1	Virus Diseases (Viral Diseases) 12/2021
1	Disease Progression 12/2021
1	Cardiac Arrhythmias (Arrythmia) 11/2021
1	Facial Dermatoses 04/2021
1	Contact Dermatitis (Eczema, Contact) 04/2021
1	Anosmia 01/2021
1	Ageusia (Hypogeusia) 01/2021
1	Insulin Resistance 01/2021
1	Thrombosis (Thrombus) 01/2021

Drug/Important Bio-Agent (IBA)

19	Bronchodilator Agents (Bronchodilators)IBA 01/2022 - 01/2004
15	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2023 - 01/2017
11	Tiotropium Bromide (Spiriva)FDA Link 11/2017 - 01/2004
10	Formoterol Fumarate (Oxis)FDA Link 01/2018 - 01/2004
9	Muscarinic AntagonistsIBA 01/2022 - 01/2016
7	Nitric Oxide (Nitrogen Monoxide)FDA Link 08/2022 - 01/2018
6	GoldIBA 01/2022 - 11/2017
5	Glycopyrrolate (Glycopyrronium Bromide)FDA LinkGeneric 01/2019 - 12/2015
4	Immunoglobulin E (IgE)IBA 01/2023 - 01/2021
4	Oxygen (Dioxygen)IBA 01/2023 - 08/2007
4	Biomarkers (Surrogate Marker)IBA 09/2020 - 01/2018
4	Carbon MonoxideIBA 07/2019 - 02/2012
4	indacaterolIBA 01/2019 - 06/2014
4	Cholinergic Antagonists (Anticholinergics)IBA 01/2017 - 05/2009
3	mepolizumabIBA 03/2023 - 01/2020
3	benralizumabIBA 03/2023 - 01/2020
3	SteroidsIBA 01/2023 - 01/2020
3	LeukotrienesIBA 08/2022 - 01/2002
3	Omalizumab (Xolair)FDA Link 01/2020 - 01/2018
3	Salmeterol Xinafoate (Serevent)FDA Link 02/2012 - 01/2007
2	CytokinesIBA 01/2022 - 01/2021
2	Antiviral Agents (Antivirals)IBA 12/2021 - 01/2021
2	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 12/2018
2	fibrin fragment D (D-dimer)IBA 01/2021 - 01/2020
2	AntioxidantsIBA 12/2014 - 04/2005
2	Arachidonate 5-Lipoxygenase (5 Lipoxygenase)IBA 04/2005 - 01/2002
1	Immunosuppressive Agents (Immunosuppressants)IBA 11/2023
1	Clostridium perfringens epsilon-toxinIBA 03/2023
1	Drug CombinationsIBA 12/2022
1	Leukotriene Antagonists (Leukotriene Receptor Antagonists)IBA 08/2022
1	cysteinyl-leukotrieneIBA 08/2022
1	leukotriene D4 receptor (cysteinyl leukotriene receptor)IBA 08/2022
1	Arginine (L-Arginine)FDA Link 01/2022
1	DNA (Deoxyribonucleic Acid)IBA 01/2022
1	Ascorbic Acid (Vitamin C)FDA LinkGeneric 01/2022
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 12/2021
1	Interleukin-8 (Interleukin 8)IBA 12/2021
1	Immunologic Factors (Immunomodulators)IBA 12/2021
1	1-phenyl-3,3-dimethyltriazene (PDT)IBA 12/2021
1	ChemokinesIBA 12/2021
1	Monoclonal AntibodiesIBA 12/2021
1	AnticoagulantsIBA 12/2021
1	3- (2- (4- azidobenzamidino)ethyl)- 5- hydroxyindole (SABA)IBA 11/2021
1	Irritants (Vesicants)IBA 04/2021
1	AerosolsIBA 02/2021
1	tetraiodothyroacetic acid (TA(4))IBA 01/2021
1	Immunomodulating AgentsIBA 01/2021
1	Ritonavir (Norvir)FDA Link 01/2021
1	Enoxaparin (Lovenox)FDA LinkGeneric 01/2021
1	AllergensIBA 01/2021
1	Lopinavir FDA Link 01/2021
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2021
1	TetracyclinesIBA 01/2021

Therapy/Procedure

29	Therapeutics 01/2024 - 05/2009
9	Continuous Positive Airway Pressure 01/2023 - 12/2019
5	Nebulizers and Vaporizers (Inhaler) 01/2017 - 02/2010
4	Artificial Respiration (Mechanical Ventilation) 01/2023 - 01/2019
3	Biological Therapy 08/2022 - 01/2019
3	Noninvasive Ventilation 12/2021 - 01/2021
2	Tracheostomy 12/2023 - 12/2014
2	Mechanical Ventilators (Ventilator) 10/2020 - 04/2020
1	Length of Stay 01/2023
1	Lung Transplantation 01/2023
1	Stents 01/2023
1	Immunomodulation 12/2021